We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Therapeutic-dose low-molecular-weight ...

Therapeutic-dose heparin appears to benefit noncritically-ill COVID-19 patients, but it does not reduce deaths or other adverse endpoints compared with usual-care thromboprophylaxis if it’s initiated ...

Patients with high D-dimer levels who are hospitalized with COVID-19—but not those who require ICU-level care—stand to gain a reduction in major thromboembolism and death with therapeutic-dose low ...

The anti-coagulant heparin reduces the likelihood of death from COVID-19 by 78% when administered in therapeutic doses to patients with signs of respiratory failure on admission to hospital, according ...